Browse by Poster Presenter

Skip to main content

CTOS 2023 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Q
Qian, Hailong

Ningbo Medical Center Lihuili Hospital
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Hailong Qian
Favorite
Qian, Haoran

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
Haoran Qian
Favorite
(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)
Haoran Qian
Favorite
Qian, Meifen

Department of Medical Oncology, Yixing Hospital of Traditional Chinese Medicine
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Meifen Qian
Favorite
Qi, Changsong

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute Beijing 100142, P. R. China
(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB
Changsong Qi
Favorite
Qi, Jiang

Department of Gastrointestinal Surgery, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Jiang Qi
Favorite
Qin, Jichao

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Jichao Qin
Favorite
Qin, Li-Xuan

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Li-Xuan Qin
Favorite
Qi, Peng

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Peng Qi
Favorite
Quagliuolo, Vittorio

Humanitas, Research Hospital, Milan, Italy
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Vittorio Quagliuolo
Favorite
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Vittorio Quagliuolo
Favorite
Quagliuolo, Vittorio Lorenzo

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Vittorio Lorenzo Quagliuolo
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Vittorio Lorenzo Quagliuolo
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Vittorio Lorenzo Quagliuolo
Favorite
Qu, Huayi

Peking University People's Hospital
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Huayi Qu
Favorite
Quignot, Chloé

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Chloé Quignot
Favorite
Quildrian, Sergio

University of Buenos Aires, Angel H. Roffo Institute of Oncology - Buenos Aires British Hospital
(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Sergio Quildrian
Favorite
(P 460) IMPACT OF RESIDUAL TUMOR AFTER RE-EXCISION IN PATIENTS WITH PRIOR UNPLANNED RESECTION OF EXTREMITY AND TRUNK SOFT TISSUE SARCOMAS
Sergio Quildrian
Favorite
Quillin, Kate

Sarcoma UK
(P 150) VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT
Kate Quillin
Favorite
quintana, MariaJesus

Hospital de la Santa Creu i Sant Pau
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
MariaJesus quintana
Favorite
Quizi, Jennifer

University of Ottawa
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Jennifer Quizi
Favorite
Qumseya, Amira

University of Florida
(P 13) OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Amira Qumseya
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Amira Qumseya
Favorite
Quon, Doris

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Doris Quon
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Doris Quon
Favorite
Qu, Zhe

Servier Pharmaceuticals
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Zhe Qu
Favorite